OncoMed completes patient enrollment in phase 2 trial of tarextumab in SCLC
OncoMed Pharmaceuticals has completed patient enrollment in the Phase 2 "PINNACLE" clinical trial of tarextumab (anti-Notch2/3, OMP-59R5) for the treatment of small cell lung cancer (SCLC).
Click on this link for more information.
